### **Sports Cardiology: Adolescent and Adults**

Matthew W. Martinez, MD FACC

Sports Cardiology Medical Director Team Cardiologist - New York Jets League Cardiologist – Major League Soccer

A PASSION FOR BETTER MEDICINE."



610-402-CARE LVH.org



I have no commercial interests nor financial relationships with any manufacturer of any product or class of products that are discussed in this educational activity or which is a commercial supporter of this activity.

### The Changing Face of the American Athlete - Youth



### The Changing Face of the American Athlete – High School









### The Changing Face of the American Athlete - Collegiate









### WE LOVE SPORTS IN THE US





### Heat

### Concussion



### **Nutrition**

### **First Aid**



### **Cardiac Arrest Legislation**

Act # 59

### "Janet's Law"

Reprinted January 31, 2014

#### HOUSE BILL No. 1290

DIGEST OF HB 1290 (Updated January 30, 2014 2:20 pm - DI 71)

Citations Affected: IC 16-18; IC 20-30; IC 20-34; IC 21-18; IC 25-1.

Synopsis: Health of student athletes. Adds athletic trainers to the definition of "health care provider" for purposes of laws concerning hospitals and public health measures. Requires the department of education to disseminate guidelines, information sheets, and forms to school corporations, charter schools, public schools, and accredited nonpublic schools to inform and educate coaches, student athletes, and parents and legal guardians of student athletes of the nature and risk of sudden cardiac arrest. Requires that a form acknowledging receipt of the information sheet must be returned to the student athlete's coach each year before beginning practice for an athletic activity. Requires that a student athlete who is suspected of experiencing a symptom of sudden cardiac arrest must be removed from the athletic activity at the time the symptom is identified. Provides that the student athlete may not return to practice and play until the student athlete's parent or legal guardian has been informed and the parent or legal guardian has provided permission for the student to return to practice and play. Requires the commission on higher education to disseminate guidelines, information sheets, and forms to a postsecondary

Sudden Cardiac Arrest Prevention Act

Scholastic Student Athlete Safety Act

### The Philadelphia Inquirer

Signing bill for student safety



Matters of the Heart: NJ Schools Must Comply With New Cardiac Emergency Regulations

by SHANA T. DON on SEPTEMBER 9, 2014

Students aren't the only ones headed back to school this fall. Now Jorsov municipalities and school districts are





#### STRATEGIC PRIORITIES

- 1. Cardiac health
- 2. Concussion
- 3. Doping and substance abuse
- 4. Mental health
- 5. Nutrition, sleep and performance
- 6. Overuse injuries and periodization
- 7. Sexual assault and interpersonal violence
- 8. Athletics health care administration
- 9. Data-driven decisions





#### Cardiovascular Care Checklist of Best Practices for NCAA Member Institutions

This checklist can be used as a resource when evaluating institutional cardiac care plans. The checklist has been designed to help institutions become better informed and educated about the best practices that are endorsed in the Interassociation Consensus Document on Cardiovascular Care of College Student-Athletes.

#### **Pre-Participation Evaluation of Student-Athletes**



### **Comparison of Screening Strategies for Elite Athletes**

|                                    | IOC/<br>USOC | FIFA | MLB | MLS | NBA/<br>WNBA | NFL | NHL | Premier<br>League                               |
|------------------------------------|--------------|------|-----|-----|--------------|-----|-----|---|
| Combine                            |              |      |     |     | Х            | Х   | Х   |   |
| H&P                                | Xા           | Xı   | Х   | Х   | Х            | Х   | Xı  | Х   |
| ECG                                | Х            | Х    | Х   | Х^  | Х            | Х   | Х   | Х^  |
| Echo                               |              | Х    |     |     | Х            |     |     | Χ^  |
| Stress test<br>ECG                 | Х*           | Х*   |     |     |              |     |     |   |
| Stress<br>Echo                     |              |      |     |     | Х            |     |     |   |
| Additional<br>Testing<br>As needed | Х            | Х    | Х   | Х   | Х            | Х   | Х   | Х   |
|                                    |              |      |     |     |              |     |     | P; others use AHA<br>ears<br>G if >35 years old |

### **Athlete Cardiac Remodeling**

### Endurance





Sustained 1 4 to 5 times rest 1 1 HR & 1 SV Volumeofihablenge

Strength Activities



#### Repetitive<sup>†</sup> SBP

Systolic BP > 200 mmHg Skeletal Mus. Contraction Vasoconstriction

### Pressure Challenge

### Athlete cardiac changes


Left Chamber Dilation Myocardial Thickening

Right Chamber Dilation

Physiologic Eccentric or *Physiologic Eccentric or*  *Physiologic RV Dilation* 

### **Cardiac Remodeling**

### Aortic Regurgitation



### Volume Challenge









### Aortic Stenosis



### Pressure Challenge

Baggish et al

### The "Athlete's Heart"

Physiology vs. Pathology

leferred by: DR SEARD

### Electrical

- Sinus bradycardia
- •Voltage for chamber enlargement
- Repolarisation anomalies


Increased cavity sizeIncreased

wall hickness t

Structural

Differentiation is crucial!

### **Athlete's EKG**




### **Vagotonia**


<u>Sinus bradycardia</u> <u>Sinus arrhythmia</u> <u>First degree AVB</u> <u>ST-elevation</u> <u>Tall T waves</u>

#### **Increased chamber size**


<u>Left ventricular hypertrophy</u> <u>Incomplete RBBB</u> <u>Left atrial enlargement</u> <u>Right atrial enlargement</u>

### Detraining reverses changes





Mathew G. Wilson<sup>4</sup>, Jordan M. Prutkin<sup>5</sup>, Andre La Gerche<sup>6</sup>, Michael J. Ackerman<sup>7</sup>, Mats Borjesson<sup>8</sup>, Jack C. Salerno<sup>9</sup>, Irfan M. Asif<sup>10</sup>, David S. Owens<sup>5</sup>, Eugene H. Chung<sup>11</sup>, Michael S. Emery<sup>12</sup>, Victor F. Froelicher<sup>13</sup>, Hein Heidbuchel<sup>14,15</sup>, Carmen Adamuz<sup>4</sup>, Chad A. Asplund<sup>16</sup>, Gordon Cohen<sup>17</sup>, Kimberly G. Harmon<sup>2</sup>, Joseph C. Marek<sup>18</sup>, Silvana Molossi<sup>19</sup>, Josef Niebauer<sup>20</sup>, Hank F. Pelto<sup>2</sup>, Marco V. Perez<sup>21</sup>, Nathan R. Riding<sup>4</sup>, Tess Saarel<sup>22</sup>, Christian M. Schmied<sup>23</sup>, David M. Shipon<sup>24</sup>, Ricardo Stein<sup>25</sup>, Victoria L. Vetter<sup>26</sup>, Antonio Pelliccia<sup>27</sup>, and Domenico Corrado<sup>28</sup>




### Sudden Cardiac Death in Young Athletes

| Floor: | Refe | rred by: 46025 | Confirmed by: OHN MERIDE | етн мр |
|--------|------|----------------|--------------------------|--------|
| aVR    |      |                | <br>                     |        |
| aVL    |      |                |                          |        |
| aVF    |      |                |                          |        |
|        |      |                | <br>                     |        |
|        |      |                | <br>                     |        |

#### Structural Abnormalities

Hypertrophic cardiomyopathy RV cardiomyopathy Artery anomalies Marfan syndrome Valve disease



#### Electrical Abnormalities

Wolff Parkinson White syndrome Long QT syndrome Brugada syndrome CPVT

#### Acquired Abnormalities

Infection (myocarditis) Trauma (commotio cordis) Drugs Environment (heat/cold)

Chandra et al: JACC 61:1027, 2013

# The good, the bad and the uncertain

|                         | Prevalence | Specificity | Utility |
|-------------------------|------------|-------------|---------|
| НСМ                     | +++        | +++         | Good    |
| LQTS                    | +          | ++/+++      | OK      |
| ARVC                    | +          | +           | Poor    |
| Anomalous<br>coronaries | ++/+++     | -           | Poor    |
| Brugada                 | +          | ++          | Poor    |

# The good, the bad and the uncertain

|                         | Prevalence | Specificity | Utility | Impact |
|-------------------------|------------|-------------|---------|--------|
| HCM                     | +++        | +++         | Good    | ?      |
| LQTS                    | +          | ++/+++      | OK      | ?      |
| ARVC                    | +          | +           | Poor    | ?      |
| Anomalous<br>coronaries | ++/+++     | -           | Poor    | ?      |
| Brugada                 | +          | ++          | Poor    | ?      |

#### ORIGINAL ARTICLE

#### Outcomes of Cardiac Screening in Adolescent Soccer Players

Aneil Malhotra, M.B., B.Chir., Ph.D., Harshil Dhutia, M.B., B.S., Gherardo Finocchiaro, M.D., Sabiha Gati, M.B., B.S., Ph.D.,
Ian Beasley, M.B., B.S., Paul Clift, M.B., B.S., M.D., Charlotte Cowie, M.B., B.S.,
Antoinette Kenny, M.B., B.S., M.D., Jamil Mayet, M.B., B.S., M.D., David Oxborough, Ph.D., Kiran Patel, M.B., B.Chir., Ph.D.,
Guido Pieles, M.B., B.S., Ph.D., Dhrubo Rakhit, M.B., B.S., Ph.D.,
David Ramsdale, M.B., B.S., M.D., Leonard Shapiro, M.B., B.S., M.D.,
John Somauroo, M.B., S.S., Graham Stuart, M.B., Ch.B.,
Armanda Varnava, M.B., Chir.B., M.D., John Walsh, M.B., B.S., D.M.,
Zaheer Yousef, M.B., B.S., M.D., Maite Tome, M.D., Ph.D.,

ABSTRACT

- 11,168 English 15-17yr old soccer player
- Mandatory H&P, Exam, ECG and Echo
- 20 yr study period
- 225 (2%) with congenital, valve disorders
- 42 (0.38%) with findings assoc with SCA

#### ORIGINAL ARTICLE

#### Outcomes of Cardiac Screening in Adolescent Soccer Players

Aneil Malhotra, M.B., B.Chir., Ph.D., Harshil Dhutia, M.B., B.S., Gherardo Finocchiaro, M.D., Sabiha Gati, M.B., B.S., Ph.D.,
Ian Beasley, M.B., B.S., Paul Clift, M.B., B.S., M.D., Charlotte Cowie, M.B., B.S., Antoinette Kenny, M.B., B.S., M.D., Jamil Mayet, M.B., B.S., M.D., David Oxborough, Ph.D., Kiran Patel, M.B., B.Chir., Ph.D., Guido Pieles, M.B., B.S., Ph.D., Dhrubo Rakhit, M.B., B.S., M.D., John Somauroo, M.B., B.S., Graham Stuart, M.B., Ch.B., Armanda Varnava, M.B., Chir.B., M.D., John Walsh, M.B., B.S., D.M., Zaheer Yousef, M.B., B.S., M.D., Maite Tome, M.D., Ph.D.,

ABSTRACT

23 died
8 deaths from cardiac causes
7 (88%) due to cardiomyopathy

-2 with HCM played AMA – died


6 were not identified by screening

|   | thlete<br>No. | Sex and<br>Age | Race* | Years from<br>Screening<br>to Death | Diagnosis  | Initial Screening<br>Result     | Blind Reading<br>(Reviewer 1) | Blind Reading<br>(Reviewer 2) |
|---|---------------|----------------|-------|-------------------------------------|--|---------------------------------|-------------------------------|-------------------------------|
| 1 |               | M, 16.8 yr     | Black | 0.1                                 | Idiopathic left ventricular hypertrophy            | Negative                        | Negative                      | Negative                      |
| 2 |               | M, 16.6 yr     | Mixed | 1.0                                 | Hypertrophic cardiomyopathy                        | Abnormal ECG and echocardiogram | NA                            | NA                            |
| 3 |               | M, 16.6 yr     | Black | 3.3                                 | Hypertrophic cardiomyopathy                        | Negative                        | Negative                      | Negative                      |
| 4 |               | M, 16.3 yr     | Black | 7.7                                 | Dilated cardiomyopathy                             | Negative                        | Negative                      | Negative                      |
| 5 |               | M, 17.0 yr     | White | 7.9                                 | Arrhythmogenic right ventricular<br>cardiomyopathy | Negative                        | Negative                      | Negative                      |
| 6 |               | M, 17.2 yr     | White | 9.7                                 | Arrhythmogenic right ventricular cardiomyopathy    | Negative                        | Negative                      | Negative                      |
| 7 |               | M, 15.7 yr     | White | 11.5                                | Hypertrophic cardiomyopathy                        | Abnormal ECG and echocardiogram | NA                            | NA                            |
| 8 |               | M, 16.8 yr     | White | 13.2                                | Sudden arrhythmic death syndrome                   | Negative                        | Negative                      | Negative                      |

\* Race was reported by the athlete or the parent or guardian.

**Challenges with screening** Outcome goals? -Safety, Diagnosis, Optics, Liability/risk? Age to start? How often? Repeat? Cost and time Expertise -Who, when -How will you handle the findings?

### **Evaluation of the athlete**















### **Cardiac changes in the athlete are unique**

#### ORIGINAL ARTICLE


#### Outcomes of Cardiac Screening in Adolescent Soccer Players

Aneil Malhotra, M.B., B.Chir., Ph.D., Harshil Dhutia, M.B., B.S., Gherardo Finocchiaro, M.D., Sabiha Gati, M.B., B.S., Ph.D.,
Ian Beasley, M.B., B.S., Paul Clift, M.B., B.S., M.D., Charlotte Cowie, M.B., B.S.,
Antoinette Kenny, M.B., B.S., M.D., Jamil Mayet, M.B., B.S., M.D.,
David Oxborough, Ph.D., Kiran Patel, M.B., B.Chir., Ph.D.,
Guido Pieles, M.B., B.S., Ph.D., Dhrubo Rakhit, M.B., B.S., M.D.,
David Ramsdale, M.B., B.S., M.D., Leonard Shapiro, M.B., B.S., M.D.,
John Somauroo, M.B., B.S., Graham Stuart, M.B., Ch.B.,


### **BE PREPARED FOR THE UNDIAGNOSED**

23 died
8 deaths from cardiac causes
7 (88%) due to cardiomyopathy
-2 with HCM played AMA – died
6 were not identified by screening

### NO perfect screening process



### Initial Arrhythmic Event



### **BE PREPARED FOR THE CORRECTED**

| Sex, and Age | Race† | History and<br>Examination      | ECG Result          | Echocardiography Result  | LGE or<br>Cardia<br>MRI |   | Genetic Te<br>Result‡ | st<br>Outcome  |
|--------------|-------|---------------------------------|---------------------|--|-------------------------|---|-----------------------|--|
| BAV          |       |                                 |                     |  |                         |   |                       |  |
| Mago yr      | Black | Dyspnea,<br>diastolic<br>murmur | Left axis deviation | Fusion of right and left coronary<br>cusps and severe aortic regur-<br>gitation; LVEDD, 60 mm  | No                      | Terminated premature-<br>ly because of fa-<br>tigue | NA                    | Underwent corrective<br>surgery and returne<br>to play |
| M, 17 yr     | White | Negative                        | Normal              | Fusion of right and noncoronary<br>cusps with mixed aortic valve<br>disease; diameter of aortic root<br>at sinuses of Valsalva, 53mm | No                      | Normal  | NA                    | Underwent corrective<br>surgery and returne<br>to play |
| M, 16 yr     | White | Diastolic<br>murmur             | Normal              | Fusion of right and left coronary<br>cusps and severe aortic regur-<br>gitation; LVEDD, 63 mm  | No                      | Normal  | NA                    | Underwent corrective<br>surgery and returne<br>to play |
| САА          |       |                                 |                     |  |                         |   |                       |  |
| M to yr      | White | Negative                        | Normal              | Left coronary artery arising from<br>right sinus of Valsalva   | NA                      | Positive for myocardial ischemia                    | NA                    | Underwent corrective<br>surgery and return<br>to play  |
| M, 15 yr     | White | Negative                        | Normal              | Right coronary artery arising from<br>left sinus of Valsalva with<br>adverse course.   | NA                      | Normal  | NA                    | Underwent corrective<br>surgery and returne<br>to play |

### <u>2005</u>

### Unless your heart is perfect or the genome stays quiet, <u>NO</u> COMPETITIVE SPORTS except perhaps class IA sports.

### <u>2015</u>

A comprehensive evaluation, risk stratification, optimally treated, and appropriately informed, Return-to-Play may be possible!

### Some young athletes with heart disease cleared to play under new recommendations

By AMERICAN HEART ASSOCIATION NEWS



Michigan DT Maurice Hurst, potential firstround pick, cleared to play after heart condition diagnosis



😏 Follow

Frank Schwab Shutdown Corner March 22, 2018 NBA NHL

### Clint Dempsey cleared to play again after heart problems

- Seattle Sounders striker missed end of last season with medical condition
- Dempsey says he hopes to make return to US national team soon

Cleared by cardiologists, Sierra Leone's Alhaji Kamara joins D.C. United

#### By Steven Goff May 10, 2016

D.C. United has acquired Alhaji Kamara, a forward from Sierra Leone whose career was jeopardized by a heart condition this winter.

In the past week, the MLS cardiology consultant and a heart specialist at MedStar Georgetown University Hospital examined Kamara and determined that he could resume playing soccer, United General Manager Dave Kasper said Tuesday.

With medical clearance, United finalized a deal with Kamara's previous employer, IFK Norrkoping of Sweden. D.C. did not pay a transfer fee but will compensate the Swedish team if Kamara, 22, meets performance incentives or is sold in the future.



#### For 4 NBA players with serious heart ailments, a fraternity has helped get them through it





# Emergency Action Plans (EAP) Hands only CPR Automatic External Defibrillators



Home » About » Resources » Media Center » News

### New guidance on preventing sudden cardiac death in athletes published

NCAA, medical specialists recommend all universities have wellrehearsed emergency action plan for sudden cardiac arrest

April 15, 2016 9:37am

A major finding of the task force was the need to streamline how cardiac arrest in studentathletes is recognized and responded to. It was recommended that all universities have a written emergency action plan for treatment of cardiac arrest that is well-rehearsed, with different protocol for treatment during a practice versus during a game/championship event since treatment during a game can be vastly different due to traffic delays and access problems for emergency medical services.

The task force recommended that the emergency action plan include training anticipated responders, establishing an emergency communications system, ensuring automated external defibrillators are easily accessible and properly charged, integrating on-site response protocols with the local emergency management system, and practicing and reviewing the plan at least annually.

http://www.ncaa.org/about/resources/media-center/news/new-guidance-preventingsudden-cardiac-death-athletes-published

### **Fire Drill**



# What is your plan for Sudden Cardiac Arrest?

- CALL for help
- CPR
  - Are you trained?
  - When should you start CPR?
- **Automated External Defibrillator (AED)?** 
  - Do you have one?
  - Do you know where it is?
  - How to use it?

# **Cardiac Arrest "Drill"**

Design your plan Personnel, Equipment, Communication, Responder Role Who calls 911 Starts CPR Gets the AED




# **MLS Cardiac Arrest Plan**

## **EMERGENCY ACTION PLAN**

- Piloted at MLS All-Star 2012 and MLS Cup 2012
- MLS Playoff teams completed and submitted a venue specific emergency plan
- ALL clubs complete as part of their preseason process
- Personnel, Equipment, Communication, Responder Role

Sideline



Byron Patterson

Team Physician

(310) 995-5583





# **MLS Cardiac Arrest Plan**

## TIME OUT PROTOCOL

 Improves communication, preparedness, and coordinated response to correctly assess and assist injured athlete



- Cardiopulmonary event protocol
- Outlines the role of first responders in an emergency situation
  - Athletic Trainer(s)
  - Physician(s)
  - EMT(s)
  - Paramedic(s)



## **Start CPR – Immediately!**

## Call for help/911!



Use a unique sign for Cardiac Arrest Get the AED


## **Stabilize the patient on the field**








## **CPR is started early and ongoing**







# Sudden Cardiac Arrest "Drill"

# The Chain of Survival









Early access to care Early CPR


Early defibrillation

Early advanced care

## **Time is limited ->**

an immediate organized response is crucial.

## **Survival vs. Time to Defibrillation**



# Survival Following SCA Student Athletes

- Historical poor
- 2000-2006 survival trends for exercise-related SCA
  - -11% survival (Drezner 2008)



# Survival Following SCA Student Athletes

- Historical poor
- 2000-2006 survival trends for exercise-related SCA
  - -11% survival (Drezner 2008)
- National Registry for AED Use in Sports July 2006 to June 2007
  - -14 cases in HS student-athletes
  - -9 of 23 survivors HS student-athletes

-64% survival in HS athletes

(Drezner 2009)

# Survival Following SCA at Sporting Events



#### CORRESPONDENCE

Mobile Automated External Defibrillator Response System during Road Races

> Researchers in Japan developed a rapid mobile AED system to provide early CPR & AED intervention for runners who have

cardiac arrest during road races. In 251 races,

28 of 30 runners who had a cardiac arrest


were successfully resuscitated.

# 93% Survival

NEIN Neine Automated External Defibrillator Response System ... Correspondence from The New England Journal of Medicine — Mobile Automated External Defibrillator Response System during Road Races neim.org

N Engl J Med 2018; 379:488-489

## Signs of cardiac arrest: Sudden non-contact collapse, passed out athlete



**Take Home points Cardiac Screening** is a work in progress Best practices are still developing -Each sport, gender, geography is different -Make sure you have the expertise -How will you handle what you find?

# **Take Home points**

- Evaluating athletes is important
   Only one part of cardiac safety
   No screening evaluations will be perfect
- Athlete on field Cardiac Care
  - EAP and AED availability are is critical
  - Be prepared for the undiagnosed

## THE CHANGING FACE OF THE AMERICAN ATHLETE




# **Fitness Athlete**



# **Masters Athlete**





Waller B: Exercise and the Heart, 1985

# **38 y/o Caucasian male, Recreational marathon runner**

- History of hyperlipidemia
- <u>Meds</u>: Lipitor 20 mg daily (recently started)
- Social History: No tobacco, illicit drugs; only rare alcoholic beverage
- Family History: No history of cardiomyopathy, early CAD, sudden cardiac death; +hyperlipidemia

<u>Hyperlipidemia</u>: Diagnosed in his 20's with "unhealthy dietary habits" (high LDL-C by report was 228), <u>was</u> on simvastatin.

- Changed lifestyle habits and began running.

- Was off statins until a few months before marathon as LDL had increased over the last several years (LDL-C 185)

# **Running History**

Engaged in long-distance recreational running for approximately 15 years

- This was his 5<sup>th</sup> marathon, PR: 3:25


- Well trained, engaged in a 20 week training program, maximum mileage 40-50 miles per week


- No issues with his pre-marathon preparation

- Completed NYC marathon with a new personal best 3:15
- No issues until immediately after finish

~1 hour after returning home (~2 hours after race), complained of left sided intense chest pressure, left arm numbness, diaphoresis

- Called 911
- EMS arrives





Troponin-I Trend: 3 -> (21.2 -> 57.3 -> 195)

# What are the management strategies?

- 1 > How do a manage an athlete recovering from an MI? Statins in a runner?
- 2 > How long do they need meds?
- 3 > When can they run again?

# Treat to Reduce Risk of Events

- DAPT (dual antiplatelet therapy)
- Low Dose Beta Blockade as Tolerated
   Warn Re → Sudden Cessation
- Look for an ACE / ARB Excuse

Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 8: Coronary Artery Disease

- 1. Restrict Competition ≥ 3 mos After ACS, PTCA, CABG
- 2. Perform an EXT on Medical Regimen
- 3. Measure LV Function

Allow the muscle to heal
 Risk stratify them

# High Risk (any 1 of the following)

- Impaired LV systolic function at rest (i.e., ejection fraction less than 50%)
- Exercise-induced anginal pain, pathological dyspnea (angina equivalent) or syncope
- Exercise-induced myocardial ischemia or complex ventricular arrhythmias
- Residual hemodynamically significant stenosis of a major coronary artery

Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 8: Coronary Artery Disease

- Restrict Competition ≥ 3 mos After ACS, PTCA, CABG
- 2. Perform an EXT on Medical Regimen
- 3. Measure LV Function
- 4. Pursue Aggressive Risk Reduction

JACC: CARDIOVASCULAR IMAGING © 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION PUBLISHED BY ELSEVIER INC. VOL. 4, NO. 9, 2011 ISSN 1936-878X/\$36.00 DOI:10.1016/J.Jcmg.2011.06.013




## MR Imaging of Carotid Plaque Composition During Lipid-Lowering Therapy

A Prospective Assessment of Effect and Time Course

Xue-Qiao Zhao, MD,\* Li Dong, MD,† Tom Hatsukami, MD,‡ Binh An Phan, MD,\* Baocheng Chu, MD, PHD,† Andrew Moore, BS,\* Trevor Lane, BS,\* Moni B. Neradilek, MS,§ Nayak Polissar, PHD,§ Duane Monick, MD,|| Colin Lee, MD,¶ Hunter Underhill, MD,† Chun Yuan, PHD†

Seattle and Yakima, Washington; and Boise, Idaho

- 84 Subjects With Coronary or Carotid Disease 33 With Measureable Plaque Lipid
- 3 Yrs. of Intensive Lipid Therapy
- With <u>Statins</u>, Niacin, Bile Sequestrant Resins



LRNC=Lipid Rich Necrotic Core

Zhao et al. JACC-Imaging 2011

## Review

A systematic review of the time course of atherosclerotic plaque regression

Adam M. Noyes<sup>a</sup>, Paul D. Thompson<sup>b,\*</sup>

- Systematic review of studies analyzing atherosclerotic regression on lipid therapy
- 31/50 studies demonstrated <u>plaque regression</u> in carotid (11), coronary (16), and aortic (4) vascular beds on statins
- Average of <u>19.7 months</u>
- Average reduction in LDL-C was 40% (in studies demonstrating regression)
- Higher regression with increased LDL reduction and higher dose statin therapy

# Treat to Reduce Risk of Events

DAPT (dual antiplatelet therapy)

- Low Dose Beta Blockade as Tolerated
  - Warn Re → Sudden Cessation
- Look for an ACE / ARB Excuse
- Aggressive Lipid Treatment -
  - → She/He Levels Are Too High for them

Less Plaque Cholesterol Less Inflammation Fewer WBCs Less Matrix Metalloproteinase

? Less chance of plaque rupture

Less Plaque Cholesterol Less Inflammation Fewer WBCs Less Matrix Metalloproteinase

? Less chance of plaque rupture

## Suggest:

18 months to 2 Years of Intensive Lipid Therapy

Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 8: Coronary Artery Disease

## It is Reasonable To:

- Restrict Competition ≥ 3 mos After ACS, PTCA, CABG
- 2. Perform an EXT on Medical Regimen
- 3. Measure LV Function
- 4. Pursue Aggressive Risk Reduction
- 5. Allow Adults to Participate in Decision
- 6. Discuss risk based available data

### **Case Presentation**


50-year-old man Marathoner -> 15 events lifetime No symptoms No CV risk factors


### **Case Presentation**

## Family history of CAD

 Multiple family members with CAD
 Earliest with a heart attack at age 60


### **Case Presentation**





 TC - 188, TG = 80, LDL = 116, HDL = 56
 HR - 52 Resting BP = 122/76

#### Framingham Global Risk Assessment Cumulative Point Scale for Estimating 10-Year CHD Risk in Men and Women (Framingham point scores)



Adapted from NCEP ATP III JAMA. 2001;285:2486-2497.



# One Running Shoe in the Grave

New Studies on Older Endurance Athletes Suggest the Fittest Reap Few Health Benefits

Running can take a toll on the heart that essentially eliminates the benefits of exercise. "Running too far, too fast and for too many years may speed one's progress toward the finish line of life," concludes an editorial to be published in the British journal Heart.

### **Can you exercise too much?**

#### Exercise and fitness Exercise and death: Am I safer on the couch?

Last Updated October 4, 2006

**CBC** News

#### the event.

A year earlier, a 42-year-old man from Guelph, Ont., died a couple of kilometres before the finish. The cause of his death was never released, but a heart attack is suspected.

Two years earlier, an experienced marathoner died running the Toronto marathon. An autopsy showed a congenital heart defect that had previously gone undetected.

"To complete a half marathon demands regular exercise and discipline to get out there and train. More so for the full marathon distance," Jay Glassman, race director for the Toronto Marathon, told CBC News. "There are obvious stresses on your heart but in all the cases that we've experienced over the past five years, we know those gentlemen were in good shape and had regularly exercised."

However, being in top physical shape won't necessarily protect you from heart disease.

Perhaps the highest profile running death was that of Jim Fixx, the journalist-turned-fitness guru who was credited with giving birth to the first running boom in the 1970s.

Fixx was an overweight smoker before he took up running. His blood cholesterol levels were elevated. He had also experienced several warning symptoms, which he chose to ignore and had refused the option of undergoing an exercise stress test



Jogging guru Jim Fixx is shown in this 1980 file photo. (CP Photo)




SPORTS

#### One Running Shoe in the Grave New Studies on Older Endurance Athletes Suggest the Fittest Reap Few Health Benefits

### 1) Are athletes at risk for CAD?

# 2) Can and how to return athletes to sportwith known CAD ?



### **Can you exercise too much?**

#### Endurance runners at risk for calcified coronary plaque

March 15, 2010

Facebook

in Share

#### American College of Cardiology 59th Annual Scientific Sessions

#### See Also

Controlling BP, cholesterol may halve risk for heart disease ...

Longer duration of obesity tied to higher risk for coronary ...

Certain antibiotics may increase risk for statin toxicity in older ...

ATLANTA – Runners of multiple marathons appear to have more calcified plaque in their coronary arteries than those who are not endurance athletes.

Tweet

A new study found that long-term endurance running in marathon runners was associated with significantly increased calcified coronary plaque volume compared with non-marathon runners (274 mm<sup>3</sup> vs. 169 mm<sup>3</sup>), according to data presented at the American College of Cardiology 59th Annual Scientific Sessions.

"The results were surprising, and extremely counterintuitive," **Jonathon G. Schwartz, MD,** of the department of internal medicine at University of Colorado, Denver, said in a press release. "Not only were elite runners just as likely as sedentary people to have calcium plaque in their coronary arteries, they actually appear to have more."

### **Coronary artery calcium and exercise**



European Heart Journal (2008) **29**, 1903–1910 doi:10.1093/eurheartj/ehn163

### Running: the risk of coronary events<sup> $\dagger$ </sup>

Prevalence and prognostic relevance of coronary atherosclerosis in marathon runners

- Conventional FRS underestimates risk of marathon runners.
- Higher CAC rates (>100) in marathon runners when compared with FRS-matched controls (36.1 vs. 21.8%, P< 0.01)</li>

### **Coronary artery calcium and exercise**



European Heart Journal (2008) **29**, 1903–1910 doi:10.1093/eurheartj/ehn163

### Running: the risk of coronary events<sup> $\dagger$ </sup>

Prevalence and prognostic relevance of coronary atherosclerosis in marathon runners

- Conventional FRS underestimates risk of marathon runners.
- Higher CAC rates (>100) in marathon runners when compared with FRS-matched controls (36.1 vs. 21.8%, P< 0.01)</li>


- A <u>zero</u> CAC score was more frequent in marathon runners than in age-matched controls


#### Running: the risk of coronary events<sup>†</sup>


**P**revalence and prognostic relevance of coronary atherosclerosis in marathon runners

#### Risk factors/test results at Normal range<sup>a</sup> Subjects with an event during follow-up baseline 55 62 Age (years) 66 64 BMI (kg/m<sup>2</sup>) 22.5 246 220 220 <25 105/67<sup>b</sup> 153/96 138/82 <120/80 Systolic blood pressure (mmHg) 110/61 No History of hypertension Yes No Yes No 344 Total cholesterol (mg/dL) 201 233 240 < 240LDL cholesterol (mg/dL) 170 98 131 < 160116 >40 HDL cholesterol (mg/dL) 109 60 100 65 Former Smoking status Former Never Former Never 7 The lower the 10-year Framingham risk score (%) 10 8 6 better CAC score (Agatston units) 874 472 171 128 7em CAC zero CAC 81 73 60 CAC percentile rank 86 Yes No Myocardial LGE Yes No Yes Resting heart rate (b.p.m.) 48 58 63 42 50 - 100Weekly MET 4241 4806 8296 5054 Marathons completed (no.) 14 22 65 140 Findings on invasive angiography Three-VD Two-VD Myocardial bridge/ Three-VD One-VD Type of event VT during exercise, Stent/ Stent VT during exercise, CARC CARG Exercise does not make you bulletproof

#### Table 4 Risk factors and test results of participants with events during follow-up







### Cardiac CT


#### **Coronary Calcium**



- Agatston score: weighted sum
- CAC indicates plaque burden
  - Calcification is one aspect of atherosclerosis
- CAC does not indicate % stenosis

55 yo






Calcium score >100




#### Calcium score ZERO

48 yo



Calcium score >400

## **CAC and prognosis**



Budoff MJ et al JACC 2007

### **Coronary Artery Calcification**

- Do athletes have more CAC? → Probably
  - Is exercise causative? → probably not
    - Cross sectional data only
      - Bias  $\rightarrow$  selection bias
      - Confounding and unmeasured risk factors
        - Accrued Lifetime Risk
        - Dietary History
        - Events prior to becoming a runner
- Does CAC carry same prognosis in athletes as nonathletes? ——
- Does treatment guided by CAC in athletes change outcomes →

JAMA Cardiology | Original Investigation

Association of All-Cause and Cardiovascular Mortality With High Levels of Physical Activity and Concurrent Coronary Artery Calcification

Laura F. DeFina, MD; Nina B. Radford, MD; Carolyn E. Barlow, PhD; Benjamin L. Willis, MD, MPH; David Leonard, PhD; William L. Haskell, PhD; Stephen W. Farrell, PhD; Andjelka Pavlovic, PhD; Katelyn Abel; Jarett D. Berry, MD; Amit Khera, MD, MSc; Benjamin D. Levine, MD

JAMA Cardiology | Original Investigation


Association of All-Cause and Cardiovascular Mortality With High Levels of Physical Activity and Concurrent Coronary Artery Calcification

Laura F. DeFina, MD; Nina B. Radford, MD; Carolyn E. Barlow, PhD; Benjamin L. Willis, MD, MPH; David Leonard, PhD; William L. Haskell, PhD; Stephen W. Farrell, PhD; Andjelka Pavlovic, PhD; Katelyn Abel; Jarett D. Berry, MD; Amit Khera, MD, MSc; Benjamin D. Levine, MD

- 21,758 men without prevalent cardiovascular disease (CVD).
- Observation study of those with physical activity and a CAC.
- Self-reported physical activity by METs (min/wk) categorized
- >3000 (n = 1561),1500 to 2999 (n = 3750), and less than 1500 (n = 16 447)
- CAC scores were less than 100 or over 100 AU
  Mean 10yr follow up

#### Table 1. Baseline Characteristics of 21758 Generally Healthy Men by Physical Activity Level and CAC Categories<sup>a</sup>

|   | Physical Activity Category, MET-min/wk |                         |                     |                      |                     |                        |                    |                      |                         |
|---|--|-------------------------|---------------------|----------------------|---------------------|------------------------|--------------------|----------------------|-------------------------|
|   | CAC <100 AU                            |                         |                     |                      | CAC ≥100 AU         |                        |                    |                      |                         |
| Characteristic                                    | <1500<br>(n = 12 413)                  | 1500-2999<br>(n = 2902) | ≥3000<br>(n = 1129) | P Value<br>for Trend | <1500<br>(n = 4034) | 1500-2999<br>(n = 848) | ≥3000<br>(n = 432) | P Value<br>for Trend | All Men<br>(N = 21 758) |
| Age, mean (SD), y                                 | 49.5<br>(7.1)                          | 49.2<br>(7.0)           | 50.0<br>(7.2)       | .97                  | 58.7<br>(8.5)       | 57.9<br>(8.2)          | 58.9<br>(8.5)      | .10                  | 51.7<br>(8.4)           |
| White, No. (%)                                    | 11 196<br>(90.2)                       | 2616<br>(90.1)          | 1021<br>(90.4)      | .07                  | 3681<br>(91.2)      | 775<br>(91.4)          | 390<br>(90.3)      | .07                  | 19679<br>(90.4)         |
| Current smoker, No. (%)                           | 1874<br>(15.1)                         | 306<br>(10.5)           | 136<br>(12.0)       | <.001                | 583<br>(14.5)       | 98<br>(11.6)           | 47<br>(10.9)       | <.001                | 3044<br>(14.0)          |
| Statin use, No. (%)                               | 1590<br>(12.8)                         | 302<br>(10.4 <u>)</u>   | 131<br>(11.6)       | <.001                | 1346<br>(33.4)      | 287<br>(33.8)          | 114<br>(26.4)      | .046                 | 3770<br>(17.3)          |
| Calcium level,<br>mean (SD), mg/dL                | 9.2<br>(0.4)                           | 9.2<br>(0.4)            | 9.2<br>(0.4)        | .046                 | 9.2<br>(0.4)        | 9.2<br>(0.4)           | 9.2<br>(0.4)       | .04                  | 9.2<br>(0.4)            |
| Framingham Risk Score,<br>mean (SD), %            | 8.7<br>(5.4)                           | 7.4<br>(4.7)            | 7.6<br>(4.8)        | <.001                | 13.5<br>(8.0)       | 11.5<br>(6.9)          | 12.3<br>(7.4)      | <.001                | 9.5<br>(6.3)            |
| Physical activity level,<br>mean (SD), MET-min/wk | 473.8<br>(469.2)                       | 2077.9<br>(416.7)       | 4618.2<br>(2431.5)  | <.001                | 430.7<br>(470.2)    | 2087.1<br>(422.4)      | 4646.9<br>(2187.9) | <.001                | 1040.6<br>(1399.6)      |
| Physical activity,<br>mean (SD), min/wk           | 104.0<br>(115.8)                       | 334.4<br>(179.2)        | 712.8<br>(447.8)    | <.001                | 105.2<br>(157.6)    | 353.8<br>(136.2)       | 766.5<br>(415.0)   | <.001                | 189.4<br>(247.5)        |
| Lifetime physical<br>activity, mean (SD), y       | 18.1<br>(13.3)                         | 22.8<br>(13.6)          | 25.5<br>(13.6)      | <.001                | 20.1<br>(15.2)      | 26.0<br>(15.1)         | 30.2<br>(16.3)     | <.001                | 20.5<br>(14.2)          |
| CAC score,<br>mean (SD), AU                       | 11.3<br>(22.7)                         | 10.3<br>(21.5)          | 11.5<br>(22.2)      | .42                  | 736.1<br>(975.9)    | 680.9<br>(865.2)       | 806.7<br>(1119.9)  | .92                  | 187.4<br>(572.1)        |
| Calcification volume<br>score, mean (SD)          | 11.0<br>(28.7)                         | 10.2<br>(18.2)          | 11.5<br>(18.6)      | .32                  | 442.9<br>(539.8)    | 410.4<br>(488.1)       | 474.0<br>(592.4)   | .91                  | 128.3<br>(572.1)        |
| No. of calcification<br>lesions, mean (SD)        | 1.1<br>(2.1)                           | 1.0<br>(1.7)            | 1.2<br>(2.7)        | .41                  | 12.5<br>(12.8)      | 11.8<br>(9.8)          | 12.1<br>(8.6)      | .33                  | 4.2<br>(8.2)            |
| Cardiorespiratory fitness,<br>mean (SD), MET      | 11.0<br>(1.9)                          | 12.4<br>(2.0)           | 12.9<br>(2.3)       | <.001                | 10.1<br>(2.0)       | 11.4<br>(2.1)          | 11.8<br>(2.2)      | <.001                | 11.2<br>(2.1)           |
| Vo <sub>2</sub> max, mean (SD),<br>mL/kg/min      | 38.6<br>(6.8)                          | 43.3<br>(7.0)           | 45.1<br>(8.0)       | <.001                | 35.4<br>(6.9)       | 40.1<br>(7.4)          | 41.3<br>(7.8)      | <.001                | 39.2<br>(7.4)           |
| Vo₂max ≥50 mL/kg/min,<br>No. (%)                  | 571<br>(5.3)                           | 439<br>(16.9)           | 246<br>(24.7)       | <.001                | 68<br>(2.2)         | 65<br>(9.2)            | 48<br>(13.4)       | <.001                | 1437<br>(7.7)           |



|                                 | Physical Activity     |                         |                    |                     |                        |                    |                         |
|---------------------------------|-----------------------|-------------------------|--------------------|---------------------|------------------------|--------------------|-------------------------|
|                                 | CAC <100 AU           |                         |                    | CAC ≥100 AU         |                        |                    |                         |
| Outcome                         | <1500<br>(n = 12 413) | 1500-2999<br>(n = 2902) | ≥3000<br>(n = 112° | <1500<br>(n = 4034) | 1500-2999<br>(n = 848) | ≥3000<br>(n = 432) | All Men<br>(N = 21 758) |
| lean (SD) follow-up time, y     | 10.5 (4.3)            | 9.8 (4.3)               | 9.6 (4.4)          | 10.8 (4.3)          | 10.5 (4.2)             |                    | 10.4 (4.3)              |
| otal follow-up, y               | 130 060.6             | 28 491.3                | 10782.9            | 43 544.1            | 8912.4                 | 4424.0             | 226 215.3               |
| ll-cause deaths                 |                       |                         |                    |                     |                        |                    |                         |
| No. of deaths                   | 282                   | 42                      | 14                 | 343                 | 52                     | 26                 | 759                     |
| Incidence per 1000 person-years | 2.2                   | 1.5                     | 1.3                | 7.9                 | 5.8                    | 5.9                | 3.4                     |
| VD deaths                       |                       |                         |                    |                     |                        |                    |                         |
| No. of deaths                   | 50                    | 7                       | 4                  | 102                 | 11                     | 4                  | 180                     |
| Incidence per 1000 person-years | 0.4                   | 0.2                     | 02                 | 2.3                 | 1.2                    | 8                  | 0.8                     |

### **Exercise and CAC**

# 1) Lower CAC is Better, ZERO is best 2) Exercise does not prevent

### atherosclerosis

### **Exercise and CAC**

- 1) Lower CAC is Better, ZERO is best
- 2) Exercise does not prevent atherosclerosis
- 3) If you have elevated CAC
  - control risk factors and increase fitness
- 4) No need to stop (or even cut back) on exercise just because of CAC

Figure 2. Relative Risk of Prevalent Coronary Artery Calcification (CAC)




Table 2. All-Cause and Cardiovascular Disease Mortality in 21758 Generally Healthy Men by Physical Activity Category and CAC Category

|                                 | Physical Activity     |                         |                     |                     |                        |                    |                        |  |
|---------------------------------|-----------------------|-------------------------|---------------------|---------------------|------------------------|--------------------|------------------------|--|
|                                 | CAC <100 AU           |                         |                     | CAC ≥100 AU         |                        |                    | _                      |  |
| Outcome                         | <1500<br>(n = 12 413) | 1500-2999<br>(n = 2902) | ≥3000<br>(n = 1129) | <1500<br>(n = 4034) | 1500-2999<br>(n = 848) | ≥3000<br>(n = 432) | All Men<br>(N = 21758) |  |
| Mean (SD) follow-up time, y     | 10.5 (4.3)            | 9.8 (4.3)               | 9.6 (4.4)           | 10.8 (4.3)          | 10.5 (4.2)             | 10.2 (4.3)         | 10.4 (4.3)             |  |
| Total follow-up, y              | 130 060.6             | 28 491.3                | 10782.9             | 43 544.1            | 8912.4                 | 4424.0             | 226 215.3              |  |
| All-cause deaths                |                       |                         |                     |                     |                        |                    |                        |  |
| No. of deaths                   | 282                   | 42                      | 14                  | 343                 | 52                     | 26                 | 759                    |  |
| Incidence per 1000 person-years | 2.2                   | 1.5                     | 1.3                 | 7.9                 | 5.8                    | 5.9                | 3.4                    |  |
| CVD deaths                      |                       |                         |                     |                     |                        |                    |                        |  |
| No. of deaths                   | 50                    | 7                       | 2                   | 102                 | 11                     | 8                  | 180                    |  |
| Incidence per 1000 person-years | 0.4                   | 0.2                     | 0.2                 | 2.3                 | 1.2                    | 1.8                | 0.8                    |  |
|                                 |                       |                         |                     |                     |                        |                    |                        |  |

Abbreviati

Table 3. Hazards for All-Cause and CVD Mortality in 21758 Generally Healthy Men by CAC and Physical Activity Category

|                                | CAC Category, HR (95% CI) |                             |                  |                             |  |  |  |  |  |
|--------------------------------|---------------------------|-----------------------------|------------------|-----------------------------|--|--|--|--|--|
| Physical Activity<br>Category, | <100 AU                   |                             | ≥100 AU          |                             |  |  |  |  |  |
| MET-min/wk                     | Age-Adjusted              | Fully Adjusted <sup>a</sup> | Age-Adjusted     | Fully Adjusted <sup>a</sup> |  |  |  |  |  |
| All-cause mortality            |                           |                             |                  |                             |  |  |  |  |  |
| <1500                          | 1 [Reference]             | 1 [Reference]               | 1 [Reference]    | 1 [Reference]               |  |  |  |  |  |
| 1500-2999                      | 0.73 (0.53-1.01)          | 0.78 (0.56-1.07)            | 0.82 (0.62-1.10) | 0.87 (0.65-1.17)            |  |  |  |  |  |
| ≥3000                          | 0.55 (0.32-0.94)          | 0.52 (0.29-0.91)            | 0.72 (0.49-1.08) | 0.77 (0.52-1.15)            |  |  |  |  |  |
| CVD mortality                  |                           |                             |                  |                             |  |  |  |  |  |
| <1500                          | 1 [Reference]             | 1 [Reference]               | 1 [Reference]    | 1 [Reference]               |  |  |  |  |  |
| 1500-2999                      | 0.69 (0.31-1.52)          | 0.66 (0.29-1.51)            | 0.58 (0.31-1.09) | 0.66 (0.36-1.23)            |  |  |  |  |  |
| ≥3000                          | 0.45 (0.11-1.83)          | 0.39 (0.08-1.79)            | 0.75 (0.36-1.54) | 0.80 (0.39-1.64)            |  |  |  |  |  |

#### AMA 2019

# Take home points

- Exercise is safe and improves CV risk
  - Exercise does not eliminate CAD risk
- Post infarction therapy can be tailored to the athlete
  - usual care is employed for at least 18 months
- Assessment of ischemia, LV function and symptoms are key to determine risk

# Thank you



### Matthew w.Martinez@lvhn.org 507-358-4993